Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as antiĀ–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

ERIS's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.885000
forwardPE 28.717676
debtToEquity 75.737000
earningsGrowth 0.322000
revenueGrowth 0.284000
grossMargins 0.752020
operatingMargins 0.249270
trailingEps 25.780000
forwardEps 41.650000

ERIS's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
With positive growth in both earnings and revenue, Eris Lifesciences Limited is expected to grow its business. These indicators highlight a strong financial outlook, with the company on track for continued expansion and increasing profitability.
ERIS's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
With ERIS's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in ERIS's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for ERIS
Price projections for ERIS

Over time, price projections for ERIS have gradually increased, reflecting rising confidence in the company's future performance. This upward trend suggests analysts expect ERIS to continue on a positive growth trajectory.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Eris Lifesciences Limited has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view Eris Lifesciences Limited as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.